Clinician Recommendation of 12-Step Meeting Attendance and Discussion regarding Disclosure of Buprenorphine use among Patients in Office-Based Opioid Treatment

Suzuki, Joji; Dodds, Tyler J.

doi:10.1080/08897077.2015.1132292

Cited by 18 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hierarchies can function as an impediment to peer support and deter women from treatment engagement. Considering the range of hierarchies [ 48 , 49 ] that may be present between women in clinical- and community-based treatment settings may offer important direction for future iterations of women-specific MOUD treatment programming. To be trauma-informed [ 50 ], women-specific treatment programs should address relational factors that impact women [ 51 , 52 , 53 ], and incorporate guidelines for skill-building to improve communication so these groups can be sources of positive social support.…”

Section: Discussionmentioning

confidence: 99%

Women-Reported Barriers and Facilitators of Continued Engagement with Medications for Opioid Use Disorder

Fiddian-Green

Gubrium

Harrington

et al. 2022

IJERPH

View full text Add to dashboard Cite

Opioid-related fatalities increased exponentially during the COVID-19 pandemic and show little sign of abating. Despite decades of scientific evidence that sustained engagement with medications for opioid use disorders (MOUD) yields positive psychosocial outcomes, less than 30% of people with OUD engage in MOUD. Treatment rates are lowest for women. The aim of this project was to identify women-specific barriers and facilitators to treatment engagement, drawing from the lived experience of women in treatment. Data are provided from a parent study that used a community-partnered participatory research approach to adapt an evidence-based digital storytelling intervention for supporting continued MOUD treatment engagement. The parent study collected qualitative data between August and December 2018 from 20 women in Western Massachusetts who had received MOUD for at least 90 days. Using constructivist grounded theory, we identified major themes and selected illustrative quotations. Key barriers identified in this project include: (1) MOUD-specific discrimination encountered via social media, and in workplace and treatment/recovery settings; and (2) fear, perceptions, and experiences with MOUD, including mental health medication synergies, internalization of MOUD-related stigma, expectations of treatment duration, and opioid-specific mistrust of providers. Women identified two key facilitators to MOUD engagement: (1) feeling “safe” within treatment settings and (2) online communities as a source of positive reinforcement. We conclude with women-specific recommendations for research and interventions to improve MOUD engagement and provide human-centered care for this historically marginalized population.

show abstract

Section: Discussionmentioning

confidence: 99%

Women-Reported Barriers and Facilitators of Continued Engagement with Medications for Opioid Use Disorder

Fiddian-Green

Gubrium

Harrington

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…22,23 In the current results, some prescribers had concerns about whether 12-step meetings in their community were accepting of patients receiving buprenorphine treatment, a concern that has also been raised by patients. 24 In addition, it is important to note that buprenorphine prescribers are required to be able to refer patients to PIs, but referrals are not mandatory. 4 The contrast we see between limited evidence on PIs to date and the importance prescribers place on PIs and their utilization may reflect the need by prescribers to address comorbid psychiatric and other substance use disorders, which are highly prevalent in this patient population.…”

Section: Discussionmentioning

confidence: 99%

Perceived need and availability of psychosocial interventions across buprenorphine prescriber specialties

Lin

Lofwall

Walsh

et al. 2019

Addictive Behaviors

View full text Add to dashboard Cite

Introduction: Psychosocial interventions are often recommended as part of buprenorphine treatment for patients with opioid use disorder, but little is known about prescriber perspectives of their use and how this varies across buprenorphine prescriber specialties. Methods: A large US sample of physicians actively prescribing buprenorphine (N=1,174) was surveyed from July 2014 to January 2017. Analyses examined prescriber characteristics and their perceptions and use of psychosocial interventions across three groups of physicians: primary care providers (PCPs), addiction physicians/psychiatrists, and other physicians. Results: Across all prescribers, 93.3% (n=1,061) report most patients would benefit from formal counseling during buprenorphine treatment while only 36.4% (n=414) believe there are adequate numbers of counselors in their community. Among addiction physicians/psychiatrists, 75.9% Lewei (Allison) Lin (corresponding author),

show abstract

“…Understanding these nuances is important for treatment professionals. A survey of patients receiving bup-nx found that a considerable percentage (30%) were worried about encountering negative attitudes toward their buprenorphine use; only 33% of participants reported that their providers had discussed disclosing their buprenorphine use 27 . Monico and colleagues 23 found that NA members receiving buprenorphine used various strategies to deal with this issue, including limiting disclosure of their buprenorphine prescriptions and avoiding particular meetings.…”

Section: Many Patients Have Encountered the Traditional View Held By mentioning

confidence: 99%

Correlates of Opioid Abstinence in a 42-Month Posttreatment Naturalistic Follow-Up Study of Prescription Opioid Dependence

Weiss

Griffin

Marcovitz

et al. 2019

J. Clin. Psychiatry

View full text Add to dashboard Cite

Objective: The natural course of prescription opioid use disorder has not been examined in longitudinal studies. The current study examined correlates of opioid abstinence over time after completing a treatment trial for prescription opioid dependence. Methods: The multi-site Prescription Opioid Addiction Treatment Study (POATS) examined different durations of buprenorphine-naloxone and different intensities of counseling to treat prescription opioid dependence, as assessed by DSM-IV; a longitudinal study was conducted following the clinical trial, from March 2009-January 2013. At 18, 30, and 42 months after treatment entry, telephone interviews were conducted (N=375). In this exploratory, naturalistic study, logistic regression analyses examined the association between treatment modality (including formal treatment and mutual help) and opioid abstinence rates at the follow-up assessments. Results: At the three follow-up assessments, approximately half of the participants reported engaging in current substance use disorder treatment (47-50%). The most common treatments were buprenorphine maintenance (27-35%) and mutual-help group attendance (27-30%), followed by outpatient counseling (18-23%) and methadone maintenance (4%). In adjusted analyses, current opioid agonist treatment showed the strongest association with current opioid abstinence (ORs=5.4, 4.6, and 2.8 at the three assessments), followed by current mutual-help

show abstract

Clinician Recommendation of 12-Step Meeting Attendance and Discussion regarding Disclosure of Buprenorphine use among Patients in Office-Based Opioid Treatment

Cited by 18 publications

References 8 publications

Women-Reported Barriers and Facilitators of Continued Engagement with Medications for Opioid Use Disorder

Women-Reported Barriers and Facilitators of Continued Engagement with Medications for Opioid Use Disorder

Perceived need and availability of psychosocial interventions across buprenorphine prescriber specialties

Correlates of Opioid Abstinence in a 42-Month Posttreatment Naturalistic Follow-Up Study of Prescription Opioid Dependence

Contact Info

Product

Resources

About